Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ragnar Nortvedt has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Effect of a Polypeptide Based Vaccine on Fish Welfare and Infestation of Salmon Lice, Lepeophtheirus salmonis, in Sea Cages with Atlantic Salmon (Salmo salar L.)

    by Ragnar Nortvedt, Erik Dahl-Paulsen, Laura Patricia Apablaza Bizama, Amritha Johny, Erik Slinde

    A new polypeptide vaccine towards salmon lice (Lepeophtheirus salmonis) was given to experimental groups of 2 × 8000 Atlantic salmon parr (Salmo salar L.), following the vaccination of a total of 4 × 8000 parr with a common set of vaccines used in Norwegian aquaculture to prevent infestation in salmon growing at sea. The remaining 2 × 8000 salmon served as control. The trial was conducted at a sea farm research facility at Knappen-Solheim in Masfjorden, Norway. Natural infestation with sea lice were staged and counted once a week from January–December 2023. The infestation was never above two mature female lice per salmon, the maximum limit set specifically for the present trial by the Norwegian Food Safety Authorities, thus delousing with chemicals or other methods was avoided. Mortality, growth, feed consumption, sexual maturation, slaughter quality, and welfare quality parameters were not significantly different between vaccinated and control salmon. The effect size showed a moderate positive difference of 0.07 mature female salmon lice per salmon in favor of the vaccinated groups from a fish size above 600 g in May until November. All fish were slaughtered and marketed at a size of 5.8 kg (>83% superior quality).


  • Open Access

    The Effect of a Polypeptide on Fish Welfare and Infestation of Salmon Lice, Lepeophtheirus salmonis, in Sea Cages with Atlantic Salmon (Salmo salar L.)

    by Ragnar Nortvedt, Erik Dahl-Paulsen, Laura Patricia Apablaza Bizama, Amritha Johny, Erik Slinde

    A new polypeptide vaccine towards salmon lice (Lepeophtheirus salmonis) was given to experimental groups of 2 x 8000 Atlantic salmon parr (Salmo salar L.), following the vaccination of a total of 4 x 8000 parr with a common set of vaccines used in Norwegian aquaculture to prevent infection in salmon growing at sea. The remaining 2 x 8000 salmon served as control. The trial was conducted at a sea farm research facility at Knappen-Solheim in Masfjorden, Norway. Natural infection with sea lice were staged and counted once a week from January – December 2023. The infection was never above 2 mature female lice per salmon, maximum limit set specifically for the present trial by the Norwegian Food Safety Authorities, thus delousing with chemicals or other methods was avoided. Mortality, growth, sexual maturation, slaughter quality and welfare quality parameters were not significantly different between vaccinated and control salmon. The vaccine had a minor positive effect on salmon lice development. All fish were slaughtered and marketed at a size of 5.8 Kg (> 83 % Superior quality).

  • Optimal AC frequency range for electro-stunning of Atlantic salmon (Salmo salar)

    by Endre Grimsbø, Ragnar Nortvedt, Bjørn Tore Hjertaker, Erling Hammer, Bjorn Roth